SunBio, Inc.
KKRX:0673705,550.00
KRW
-200.00
(-3.48%)
ISIN
KR7067370007
Return %
Stock
S&P 500
1Y
-2.80
13.14
3Y
-31.99
80.78
5Y
- -
67.74
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Gwang No
- Full Time Employees
- 29
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Inchon South Korea
- IPO Date
- Jan 22, 2016
- Website
- sunbio.com
- Similar Companies
- Business
- SunBio, Inc. is a South Korea-based biotechnology and specialty biomaterials company that develops, manufactures, and commercializes biopharmaceuticals, PEGylation derivatives, and medical devices. The company focuses on proprietary PEGylation technology, a chemical modification process that attaches polyethylene glycol polymers to peptides, proteins, small molecules, and biomaterials to enhance in vivo stability, reduce immunogenicity, and extend therapeutic half-life. SunBio, Inc. operates across multiple business segments, offering a systematic portfolio of core products and services, including: high-purity activated PEG derivatives and reagents, featuring monofunctional, heterobifunctional, branched, and multi-arm PEG linkers supplied to global pharmaceutical manufacturers and research institutions; biosimilar and biobetter therapeutics, led by NeuPEG (Pelgraz / pegfilgrastim), a pegylated granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia and out-licensed globally to Intas Pharmaceuticals and Accord Healthcare, alongside developmental pipeline candidates such as PEG-erythropoietin (PEG-EPO) for anemia and PEG-uricase for refractory gout; medical device solutions, comprising MucoPEG, a 510(k)-cleared pegylated oral rinse liquid formulated for the treatment of xerostomia (dry mouth syndrome); advanced biomaterial innovations, including SBX, a pegylated hemoglobin-based oxygen carrier developed as an artificial blood substitute, and PEG-based solid-state battery electrolytes; and custom PEGylation contract development and manufacturing organization (CDMO) services supported by European Medicines Agency (EMA) and Korean Good Manufacturing Practice (GMP) compliant manufacturing infrastructure. The company serves multinational pharmaceutical developers, biotechnology firms, clinical healthcare providers, and academic research centers across North America, Europe, Latin America, and the Asia-Pacific region. In recent operational and strategic developments, SunBio, Inc. completed the comprehensive relocation and expansion of its corporate headquarters, research institute, and cGMP-compliant manufacturing facilities to Incheon in 2024 to scale up commercial PEG derivative production capacity and support clinical pipeline advancement. The company expanded its global intellectual property portfolio by securing a United States patent in 2025 for its artificial blood substitute candidate SBX following the completion of preclinical animal safety studies, while securing additional international patent grants for MucoPEG across key jurisdictions, including Japan and Australia in 2024. In addition, commercial partner Intas Pharmaceuticals broadened the international market presence of Pelgraz across Europe and Latin America, with the therapy receiving recognition as a Best Value Biologic Medicine in Ireland in 2024. As part of its strategic portfolio rationalization, SunBio, Inc. discontinued further development of its SynoGEL osteoarthritis project to concentrate financial and scientific resources on its high-value biopharmaceutical assets, artificial blood technologies, and specialty PEG chemical materials. SunBio, Inc. was founded in June 1997, listed on the KOSDAQ market under ticker 067370 in October 2022, and is headquartered in Incheon, South Korea.